Loading…
Inhibikase Therapeutics, Inc. is projected to rise to $2.52 by 2027, a +24% move from its current price of $2.04. IKT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.99 | $2.04 | $2.09 | +0.02% |
| Jul 15 | $1.97 | $2.04 | $2.11 | +0.05% |
| Jul 16 | $1.96 | $2.04 | $2.13 | +0.07% |
| Jul 17 | $1.95 | $2.04 | $2.14 | +0.09% |
| Jul 18 | $1.94 | $2.04 | $2.15 | +0.11% |
| Jul 19 | $1.93 | $2.04 | $2.16 | +0.14% |
| Jul 20 | $1.92 | $2.04 | $2.17 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.92 | $2.04 | $2.17 | +0.16% |
| Week 2 | $1.88 | $2.05 | $2.23 | +0.32% |
| Week 3 | $1.84 | $2.05 | $2.28 | +0.48% |
| Week 4 | $1.81 | $2.05 | $2.32 | +0.64% |
| Week 5 | $1.79 | $2.06 | $2.36 | +0.81% |
| Week 6 | $1.77 | $2.06 | $2.40 | +0.97% |
| Week 7 | $1.75 | $2.06 | $2.43 | +1.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH). It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for PAH, to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc.
entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT is trading at $1.99 per share, with a market capitalization of $262.74M, and ranks 3531. The current price and market position set the stage for a longer-term price outlook, as the forecast implies a multiyear upward trajectory with yearly targets through 2030 and beyond. The projections include 2026 avg of $1.99, rising toward higher levels by 2030 ($4.61 avg), 2040 ($10.58 avg), and 2050 ($26.87 avg).
Bullish sentiment is indicated across many forecast years. These figures are estimates and not guarantees, subject to market and clinical development risks.
A major floor 28.4% below — a decisive break under it would weaken the trend.
The nearest floor, 20.6% below — buyers have tended to step in here.
Price is pressing into resistance (1.5% away) — a breakout level to watch.
A major ceiling 15.7% above — clearing it would confirm fresh momentum.
Key IKT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IKT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.04 | Buy | $2.03 | Buy |
| MA 10 | $2.00 | Buy | $1.99 | Buy |
| MA 20 | $1.88 | Buy | $1.92 | Buy |
| MA 50 | $1.82 | Buy | $1.84 | Buy |
| MA 100 | $1.83 | Buy | $1.81 | Buy |
| MA 200 | $1.72 | Buy | $1.80 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.61 | Neutral |
| Stoch RSI (14) | 33.94 | Neutral |
| CCI (20) | 90.60 | Neutral |
| Williams %R (14) | -13.04 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 9.09 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 86.96 | Sell |
| TRIX (15) | 0.50 | Buy |
| Awesome (5,34) | 0.23 | Buy |
| Ultimate (7,14,28) | 59.94 | Neutral |
| Momentum (10) | 0.17 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 2.07 | Sell |
| ADX (14) | 27.23 | Buy |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows a bullish tilt with RSI14 at 70. The asset trades above both the SMA50 ($1.81) and SMA200 ($1.71), suggesting positive near-term momentum. Key levels to watch are support at $1.62 and resistance at $2.03, framing a near-term trading range.
Over the next 30 days, the low end of the range is $1.68 and the high end is $2.36, providing a defined corridor for price action. Annualized volatility stands at 50%, indicating above-average price swings relative to its price level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.50 | $2.04 | $2.67 | 0% | Neutral | |
| $2.03 | $2.52 | $3.29 | +24% | Bullish | |
| $2.23 | $2.83 | $3.82 | +39% | Bullish | |
| $2.80 | $3.62 | $5.00 | +77% | Bullish | |
| $3.37 | $4.44 | $6.26 | +118% | Bullish | |
| $3.40 | $4.54 | $6.53 | +123% | Bullish | |
| $3.66 | $4.96 | $7.26 | +143% | Bullish | |
| $3.99 | $5.48 | $8.13 | +168% | Bullish | |
| $4.11 | $5.72 | $8.61 | +180% | Bullish | |
| $5.04 | $7.10 | $10.83 | +248% | Bullish | |
| $6.60 | $9.81 | $15.82 | +381% | Bullish | |
| $14.63 | $23.87 | $41.71 | +10.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.50 | $2.04 | $2.38 | +0.00% |
| August 2026 | $1.72 | $2.02 | $2.43 | -1.02% |
| September 2026 | $1.76 | $2.08 | $2.53 | +3.16% |
| October 2026 | $1.75 | $2.08 | $2.55 | +0.00% |
| November 2026 | $1.74 | $2.08 | $2.56 | -0.29% |
| December 2026 | $1.79 | $2.15 | $2.67 | +3.53% |
Click any year to see its month-by-month IKT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IKT to range from $1.50 to $2.67 through 2026. The $2.04 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The IKT price prediction for 2027 points to an average of $2.52 (low $2.03, high $3.29) — a potential gain of +24% on today's $2.04. Momentum favours further upside here.
In 2028, IKT is projected to trade between $2.23 and $3.82, averaging $2.83 — a potential gain of +39% from today's $2.04. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Inhibikase Therapeutics, Inc.'s 2029 outlook centres on $3.62, within a $2.80 to $5.00 range. That is up +28% on the projected 2028 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2030, IKT could reach as high as $6.26, with a base case around $4.44 and support toward $3.37 — roughly +118% from $2.04. Buyers look set to stay in control over this stretch.
Expect IKT to range from $3.40 to $6.53 through 2031. The $4.54 average target implies a +123% move from current prices. That is up +2% on the projected 2030 average. Momentum favours further upside here.
The IKT price prediction for 2032 points to an average of $4.96 (low $3.66, high $7.26) — a potential gain of +143% on today's $2.04. Buyers look set to stay in control over this stretch.
In 2033, IKT is projected to trade between $3.99 and $8.13, averaging $5.48 — a potential gain of +168% from today's $2.04. That is up +10% on the projected 2032 average. Momentum favours further upside here.
Inhibikase Therapeutics, Inc.'s 2034 outlook centres on $5.72, within a $4.11 to $8.61 range. That is up +4% on the projected 2033 average. That marks a +180% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, IKT could reach as high as $10.83, with a base case around $7.10 and support toward $5.04 — roughly +248% from $2.04. Momentum favours further upside here.
Expect IKT to range from $6.60 to $15.82 through 2040. The $9.81 average target implies a +381% move from current prices. That is up +38% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The IKT price prediction for 2050 points to an average of $23.87 (low $14.63, high $41.71) — a potential gain of +10.7x on today's $2.04. Momentum favours further upside here.
Investing $1,000 in IKT today (≈ 490.196078 IKT) could be worth
$11,700.53
+$10,700.53 (+1070%) by 2050 · US Dollar
Based on the average projected IKT price of $23.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IKTwould be worth at today's price.
$1,000 invested in IKT on Jul 10, 2025 (≈ 500 IKT) would be worth
$1,020
+$20 (+2.0%) today · 1.02× · US Dollar
Based on a IKT entry price of $2 vs. today's $2.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.99 | $1,025.13 | +2.5% |
| 1 month ago | $1.66 | $1,228.92 | +22.9% |
| 3 months ago | $1.7 | $1,200 | +20.0% |
| 6 months ago | $1.71 | $1,192.98 | +19.3% |
| 1 year ago | $2 | $1,020 | +2.0% |
| All time (5.0y) ago | $14.64 | $139.34 | -86.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IKT forecast.
Our base-case forecast reaches $4.10 around 2030.
Implied market cap at $4.10: $541.33M
The multi-year forecast highlights meaningful upside, anchored by several target years. By 2030, the average price is projected at $4.61 with a minimum of $3.45 and a maximum of $6.63, yielding an ROI of 131.6% and a bullish sentiment. By 2040, the average rises to $10.58 with a maximum of $17.58 and a minimum of $6.89, delivering an ROI of 431.9% and a bullish outlook.
By 2050, the average is expected to be $26.87 with a maximum of $48.68 and a minimum of $15.72, corresponding to an ROI of 1250.5% and a bullish sentiment. Overall, the long-horizon outlook points to substantial potential upside, though these are estimates and carry inherent uncertainty and risks tied to clinical progress, regulatory approvals, and market dynamics.
Tap a question to reveal the answer.
2030: min $3.45, avg $4.61, max $6.63; ROI 131.6%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages (e.g., 2040 avg $10.58 and 2050 avg $26.87) and positive ROIs, but these are estimates, not guarantees, and depend on multiple factors.
The 2050 maximum is $48.68, which is below $50, so the forecast does not indicate a $50 level within the provided horizon.
Current price $1.99; Market cap $262.74M.
2030 avg $4.61 (ROI 131.6%, bullish), 2040 avg $10.58 (ROI 431.9%, bullish), and 2050 avg $26.87 (ROI 1250.5%, bullish). These are estimates and carry risk.
Inhibikase Therapeutics, Inc. Community Discussion
0Share your Inhibikase Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.